Recent submissions

  • Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy. 

    Romo-Morales, A; Aladowicz, E; Blagg, J; Gatz, SA; Shipley, JM (2019-06-17)
    BACKGROUND: Ewing sarcoma and desmoplastic small round cell tumors (DSRCT) are rare and clinically aggressive sarcomas usually characterized by oncogenic fusion proteins involving EWS. Emerging studies of Ewing sarcoma ...
  • The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. 

    Martínez-Vélez, N; Garcia-Moure, M; Marigil, M; González-Huarriz, M; Puigdelloses, M; Gallego Pérez-Larraya, J; Zalacaín, M; Marrodán, L; Varela-Guruceaga, M; Laspidea, V; Aristu, JJ; Ramos, LI; Tejada-Solís, S; Díez-Valle, R; Jones, C; Mackay, A; Martínez-Climent, JA; García-Barchino, MJ; Raabe, E; Monje, M; Becher, OJ; Junier, MP; El-Habr, EA; Chneiweiss, H; Aldave, G; Jiang, H; Fueyo, J; Patiño-García, A; Gomez-Manzano, C; Alonso, MM (2019-05-28)
    Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as a solid therapeutic ...
  • Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma. 

    Davidson, M; Barber, LJ; Woolston, A; Cafferkey, C; Mansukhani, S; Griffiths, B; Moorcraft, S-Y; Rana, I; Begum, R; Assiotis, I; Matthews, N; Rao, S; Watkins, D; Chau, I; Cunningham, D; Starling, N; Gerlinger, M (2019-05-27)
    DNA somatic copy number aberrations (SCNAs) are key drivers in oesophagogastric adenocarcinoma (OGA). Whether minimally invasive SCNA analysis of circulating tumour (ct)DNA can predict treatment outcomes and reveal how ...
  • Dissecting PARP inhibitor resistance with functional genomics. 

    Pettitt, SJ; Lord, CJ (2019-04-04)
    The poly-(ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib was the first licenced cancer drug that targeted an inherited form of cancer, namely ovarian cancers caused by germline BRCA1 or BRCA2 gene mutations. ...
  • Beyond DNA repair: the novel immunological potential of PARP inhibitors. 

    Chabanon, RM; Soria, J-C; Lord, CJ; Postel-Vinay, S (2019)
    Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and prostate cancers, ...
  • Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. 

    Sestak, I; Martín, M; Dubsky, P; Kronenwett, R; Rojo, F; Cuzick, J; Filipits, M; Ruiz, A; Gradishar, W; Soliman, H; Schwartzberg, L; Buus, R; Hlauschek, D; Rodríguez-Lescure, A; Gnant, M (2019-04-30)
    PURPOSE: EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we ...
  • Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia. 

    Zheng, G; Chattopadhyay, S; Sud, A; Sundquist, K; Sundquist, J; Försti, A; Houlston, R; Hemminki, A; Hemminki, K (2019-04)
    Improvement of survival in lymphocytic leukaemia has been accompanied by the occurrence of second primary cancer (SPCs). Based on Swedish Family Cancer Database, we applied bi-directional analyses in which relative risks ...
  • Resolving genetic heterogeneity in cancer. 

    Turajlic, S; Sottoriva, A; Graham, T; Swanton, C (2019-03-27)
    To a large extent, cancer conforms to evolutionary rules defined by the rates at which clones mutate, adapt and grow. Next-generation sequencing has provided a snapshot of the genetic landscape of most cancer types, and ...
  • NON-CODING NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA; THEIR CLINICAL IMPACT IN THE CLL4 CLINICAL TRIAL 

    Larrayoz, M; Rose-Zerilli, MJ; Parker, H; Blakemore, SJ; Forster, J; Davis, Z; Steele, AJ; Else, M; Catovsky, D; Oscier, DG; Strefford, JC (2016-06)
  • Reply to 'Revisiting signatures of neutral tumor evolution in the light of complexity of cancer genomic data'. 

    Williams, MJ; Werner, B; Heide, T; Barnes, CP; Graham, TA; Sottoriva, A (2018-12)
  • Association analyses identify 31 new risk loci for colorectal cancer susceptibility. 

    Law, PJ; Timofeeva, M; Fernandez-Rozadilla, C; Broderick, P; Studd, J; Fernandez-Tajes, J; Farrington, S; Svinti, V; Palles, C; Orlando, G; Sud, A; Holroyd, A; Penegar, S; Theodoratou, E; Vaughan-Shaw, P; Campbell, H; Zgaga, L; Hayward, C; Campbell, A; Harris, S; Deary, IJ; Starr, J; Gatcombe, L; Pinna, M; Briggs, S; Martin, L; Jaeger, E; Sharma-Oates, A; East, J; Leedham, S; Arnold, R; Johnstone, E; Wang, H; Kerr, D; Kerr, R; Maughan, T; Kaplan, R; Al-Tassan, N; Palin, K; Hänninen, UA; Cajuso, T; Tanskanen, T; Kondelin, J; Kaasinen, E; Sarin, A-P; Eriksson, JG; Rissanen, H; Knekt, P; Pukkala, E; Jousilahti, P; Salomaa, V; Ripatti, S; Palotie, A; Renkonen-Sinisalo, L; Lepistö, A; Böhm, J; Mecklin, J-P; Buchanan, DD; Win, A-K; Hopper, J; Jenkins, ME; Lindor, NM; Newcomb, PA; Gallinger, S; Duggan, D; Casey, G; Hoffmann, P; Nöthen, MM; Jöckel, K-H; Easton, DF; Pharoah, PDP; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; PRACTICAL consortium; Harkin, A; Allan, K; McQueen, J; Paul, J; Iveson, T; Saunders, M; Butterbach, K; Chang-Claude, J; Hoffmeister, M; Brenner, H; Kirac, I; Matošević, P; Hofer, P; Brezina, S; Gsur, A; Cheadle, JP; Aaltonen, LA; Tomlinson, I; Houlston, RS; Dunlop, MG (2019-05-14)
    Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that ...
  • Reply to 'Neutral tumor evolution?' 

    Heide, T; Zapata, L; Williams, MJ; Werner, B; Caravagna, G; Barnes, CP; Graham, TA; Sottoriva, A (2018-12)
  • ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. 

    Carvalho, D; Taylor, KR; Olaciregui, NG; Molinari, V; Clarke, M; Mackay, A; Ruddle, R; Henley, A; Valenti, M; Hayes, A; Brandon, ADH; Eccles, SA; Raynaud, F; Boudhar, A; Monje, M; Popov, S; Moore, AS; Mora, J; Cruz, O; Vinci, M; Brennan, PE; Bullock, AN; Carcaboso, AM; Jones, C (2019)
    Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brainstem tumour, with a quarter of patients harbouring somatic mutations in ACVR1, encoding the serine/threonine kinase ALK2. Despite being an amenable drug ...
  • Streamlining Detection of Fusion Genes in Colorectal Cancer: Having "Faith" in Precision Oncology in the (Tissue) "Agnostic" Era. 

    Valeri, N (2019-03-15)
    The FDA recently granted tissue-agnostic approval for the first-in-class TRK inhibitor larotrectinib for patients whose tumors harbor fusions in neurotrophic receptor tyrosine kinases. These fusion genes have a frequency ...
  • Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. 

    Fontana, E; Eason, K; Cervantes, A; Salazar, R; Sadanandam, A (2019-04-01)
    The Colorectal Cancer Subtyping Consortium identified four gene expression consensus molecular subtypes, CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal), using multiple microarray or RNA-sequencing ...
  • Second primary cancers in non-Hodgkin lymphoma: Family history and survival. 

    Chattopadhyay, S; Zheng, G; Sud, A; Sundquist, K; Sundquist, J; Försti, A; Houlston, R; Hemminki, A; Hemminki, K (2019-05-04)
    Second primary cancers (SPCs) account for an increasing proportion of all cancer diagnoses and family history of cancer may be a risk factor for SPCs. Using the Swedish Family-Cancer Database on non-Hodgkin lymphoma (NHL), ...
  • Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis. 

    Lambros, MB; Seed, G; Sumanasuriya, S; Gil, V; Crespo, M; Fontes, M; Chandler, R; Mehra, N; Fowler, G; Ebbs, B; Flohr, P; Miranda, S; Yuan, W; Mackay, A; Ferreira, A; Pereira, R; Bertan, C; Figueiredo, I; Riisnaes, R; Rodrigues, DN; Sharp, A; Goodall, J; Boysen, G; Carreira, S; Bianchini, D; Rescigno, P; Zafeiriou, Z; Hunt, J; Moloney, D; Hamilton, L; Neves, RP; Swennenhuis, J; Andree, K; Stoecklein, NH; Terstappen, LWMM; de Bono, JS (2018-11-15)
    Purpose: Circulating tumor cells (CTCs) have clinical relevance, but their study has been limited by their low frequency.Experimental Design: We evaluated liquid biopsies by apheresis to increase CTC yield from patients ...
  • Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. 

    Cremolini, C; Benelli, M; Fontana, E; Pagani, F; Rossini, D; Fucà, G; Busico, A; Conca, E; Di Donato, S; Loupakis, F; Schirripa, M; Lonardi, S; Borelli, B; Ongaro, E; Eason, K; Morano, F; Casagrande, M; Fassan, M; Sadanandam, A; de Braud, F; Falcone, A; Pietrantonio, F (2019)
    Objective: Primary tumour location is regarded as a reliable surrogate of colorectal cancer biology. Sensitivity to anti-EGFRs (Epidermal Growth Factor Receptor) of metastatic transverse colon cancers (mTCCs) has usually ...
  • miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. 

    Anandappa, G; Lampis, A; Cunningham, D; Khan, KH; Kouvelakis, K; Vlachogiannis, G; Hedayat, S; Tunariu, N; Rao, S; Watkins, D; Starling, N; Braconi, C; Darvish-Damavandi, M; Lote, H; Thomas, J; Peckitt, C; Kalaitzaki, R; Khan, N; Fotiadis, N; Rugge, M; Begum, R; Rana, I; Bryant, A; Hahne, JC; Chau, I; Fassan, M; Valeri, N (2019-04-05)
    Purpose: Anti-EGFR mAbs are effective in the treatment of metastatic colorectal cancer (mCRC) patients. RAS status and tumor location (sidedness) are predictive markers of patients' response to anti-EGFR mAbs. Recently, ...
  • miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. 

    Fassan, M; Cui, R; Gasparini, P; Mescoli, C; Guzzardo, V; Vicentini, C; Munari, G; Loupakis, F; Lonardi, S; Braconi, C; Scarpa, M; D'Angelo, E; Pucciarelli, S; Angriman, I; Agostini, M; D'Incá, R; Farinati, F; Gafà, R; Lanza, G; Frankel, WL; Croce, CM; Valeri, N; Rugge, M (2019-02)
    miR-224 has recently emerged as a driver oncomiR in sporadic colorectal carcinogenesis, but its pathogenetic role is still controversial. A large phenotypical and molecularly characterized series of preinvasive and invasive ...

View more